No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
BIOR240517P1000
- 0.30
- 0.000.00%
15min DelayClose May 9 16:00 ET
0.30High0.30Low
0.30Open0.30Pre Close1 Volume114 Open Interest1.00Strike Price30.00Turnover202.53%IV-3.04%PremiumMay 17, 2024Expiry Date0.25Intrinsic Value100Multiplier8DDays to Expiry0.05Time Value100Contract SizeAmericanOptions Type-0.7889Delta1.2779Gamma2.72Leverage Ratio-0.0039Theta-0.0002Rho-2.14Eff Leverage0.0003Vega
Intraday
- 5D
- 1D
News
Express News | Biora Therapeutics to Report First Quarter 2024 Financial Results and Provide Corporate Update
Biora Therapeutics to Present Clinical Data on Device Function of the NaviCap Oral Delivery Platform at Digestive Disease Week 2024
SAN DIEGO, May 06, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, today announced that it will present clinical data
Express News | Biora Therapeutics Inc - Final Results Are Expected to Be Available in Late Q2 2024
Express News | Biora Therapeutics Announces Completion of Multiple-Ascending Dose (Mad) Cohorts for Clinical Trial of Bt-600
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersBio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. The company's market cap stands at $3.4 million. Biora Therapeutics (NASDAQ:BIOR) share
Biora Therapeutics Receives Buy Rating Amid Positive Clinical Progress and Promising Drug Delivery Innovations
Comments
$Biora Therapeutics(BIOR.US$
NEWS
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
NEWS
Biora Therapeutics Announces Completion of Multiple-Ascending Dose (MAD) Cohorts for Clinical Trial of BT-600
1
$Biora Therapeutics(BIOR.US$ Biora Therapeutics Announces New Patent Covering Its BioJet Liquid Jet Delivery Technology
Benzinga· 2 mins ago
Benzinga· 2 mins ago
2
$Biora Therapeutics(BIOR.US$ Press Release: Biora Therapeutics Announces Closing of $6 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Dow Jones· 1 min ago
Dow Jones· 1 min ago
1
8
$Biora Therapeutics(BIOR.US$ performance targets achieved in single-ascending dose (SAD) cohorts of BT-600 clinical trial
Results demonstrated targeted drug delivery and absorption in the colon, with 3-4 times lower drug levels in blood
Remainder of BT-600 clinical trial progressing well and on schedule
Results demonstrated targeted drug delivery and absorption in the colon, with 3-4 times lower drug levels in blood
Remainder of BT-600 clinical trial progressing well and on schedule
1
$Biora Therapeutics(BIOR.US$ up tomorrow with good news
1
Read more